Ascendis Pharma A/S logo

ASND

Ascendis Pharma A/S

$104.9

Earnings Summary

Revenue
$2.51Mn
Net Profits
$-80.36Mn
Net Profit Margins
-3205.5%

Highlights

Revenue:

Ascendis Pharma A/S’s revenue fell -76.16% since last year same period to $2.51Mn in the Q4 2019. On a quarterly growth basis, Ascendis Pharma A/S has generated 11.77% jump in its revenue since last 3-months.

Net Profits:

Ascendis Pharma A/S’s net profit fell -151.3% since last year same period to $-80.36Mn in the Q4 2019. On a quarterly growth basis, Ascendis Pharma A/S has generated -220% fall in its net profits since last 3-months.

Net Profit Margins:

Ascendis Pharma A/S’s net profit margin fell -954.03% since last year same period to -3205.5% in the Q4 2019. On a quarterly growth basis, Ascendis Pharma A/S has generated -186.3% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ascendis Pharma A/S post its latest quarter earnings

EPS Estimate Current Quarter
-2.6
EPS Estimate Current Year
-2.6

Highlights

EPS Estimate Current Quarter:

Ascendis Pharma A/S’s earning per share (EPS) estimates for the current quarter stand at -2.6 - a 3.35% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ascendis Pharma A/S’s earning per share (EPS) estimates for the current year stand at -2.6.

Key Ratios

Key ratios of the Ascendis Pharma A/S post its Q4 2022 earnings

Return on Assets (ROA)
-0.32
Return on Equity (ROE)
-1.02

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ascendis Pharma A/S’s return on assets (ROA) stands at -0.32.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ascendis Pharma A/S’s return on equity (ROE) stands at -1.02.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2021-09-30
-2.29
-1.47
35.81%
2021-06-30
-2.22
-2.5
-12.61%
2021-03-31
-1.7
-1.17
31.18%
2021-12-31
-2.34
-1.87
20.09%

Company Information

Ascendis Pharma is applying its innovative TransCon technologies to build a leading, fully integrated biopharmaceutical company focused on making a meaningful difference in patients' lives. Guided by its core values of patients, science and passion, the company utilizes its TransCon technologies to create new and potentially best-in-class therapies.

Organisation
Ascendis Pharma A/S
Headquarters
Tuborg Boulevard 12, Hellerup, Denmark, 2900
Employees
797
Industry
Health Technology
CEO
Jan Moeller Mikkelsen